General American Investors Co. Inc. lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 333,600 shares of the biopharmaceutical company’s stock after selling 40,000 shares during the period. Gilead Sciences accounts for about 2.2% of General American Investors Co. Inc.’s portfolio, making the stock its 13th biggest position. General American Investors Co. Inc.’s holdings in Gilead Sciences were worth $20,867,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently bought and sold shares of GILD. Athena Capital Advisors LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $27,000. Capital Financial Planning LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $27,000. Advisors Preferred LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at $31,000. Legacy Financial Advisors Inc. boosted its holdings in shares of Gilead Sciences by 361.3% during the 4th quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 383 shares in the last quarter. Finally, Claybrook Capital LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at $32,000. Hedge funds and other institutional investors own 80.20% of the company’s stock.
GILD stock opened at $65.88 on Tuesday. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $79.61. The company has a debt-to-equity ratio of 1.19, a quick ratio of 3.30 and a current ratio of 3.38. The company has a market cap of $82.92 billion, a P/E ratio of 10.71, a PEG ratio of 4.09 and a beta of 1.16.
The company also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were paid a dividend of $0.63 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 dividend on an annualized basis and a yield of 3.83%. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s dividend payout ratio is 40.98%.
Several equities research analysts recently weighed in on the company. Maxim Group reissued a “buy” rating and set a $84.00 price objective on shares of Gilead Sciences in a report on Friday. Oppenheimer set a $85.00 price target on Gilead Sciences and gave the company a “buy” rating in a research note on Tuesday, March 19th. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, January 23rd. Mizuho set a $88.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Friday, March 22nd. Finally, BidaskClub downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, February 7th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $82.29.
In other Gilead Sciences news, Director Gayle E. Wilson sold 19,068 shares of the business’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the completion of the sale, the director now directly owns 143,567 shares of the company’s stock, valued at approximately $9,630,474.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John Francis Cogan sold 2,700 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $64.14, for a total value of $173,178.00. Following the sale, the director now directly owns 57,560 shares of the company’s stock, valued at $3,691,898.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 24,468 shares of company stock worth $1,627,948. 0.20% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://sportsperspectives.com/2019/04/02/general-american-investors-co-inc-sells-40000-shares-of-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
See Also: What is range trading?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.